HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Lorazepam
ATIVAN · (±)-Lorazepam solution · Lorazepam CIV (200 mg)I1D4040.998mg/mg(ai) · 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one · Quait · Tavor · Wypax · LORAX
Identifikatoren & physikalische Daten
| CAS No. | 846-49-1 |
|---|---|
| Summenformel | C15H10Cl2N2O2 |
| Durchschnittliche Molmasse | 321,2 g/mol |
| Monoisotopische Masse | 320,01193292 g/mol |
| SMILES | O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O |
| InChIKey | DIWRORZWFLOCLC-UHFFFAOYSA-N |
| PubChem CID | 3958 |
| ChEMBL | CHEMBL580 |
| ChEBI | CHEBI:6539 |
| EC No. | 212-687-6 |
| DTXSID | DTXSID7023225 |
| Lokaler Name | Lorazepam |
Chemische & physikalische Eigenschaften
| XLogP | 2,4 |
|---|---|
| Polarare Oberfläche (TPSA) | 61,7 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 1 |
| Schwere Atome | 21 |
| Formalladung | 0 |
| Komplexität | 443 |
| Stoffklassen | Pharmaceutical |
| Arzneimittel | DEA NFLIS-Drug Category -> BenzodiazepinesDEA Schedule IV Controlled Substance -> DepressantsPharmaceuticals -> Synthetic Cannabinoids or Psychoactive CompoundsPharmaceuticals -> Benzodiazepines |
| LogP (Verteilungskoeffizient) | 3.52.37 |
| Löslichkeit | 1.76e-02 g/LPractically insoluble in water, sparingly soluble in ethanol (96 per cent), sparingly soluble or slightly soluble in methylene chloride.54mg/L(temperature not stated) |
| Human Drugs | Breast FeedingLactationMilk, HumanHypnotics and SedativesAnti-Anxiety AgentsBenzodiazepinesFDA approved drugs -> Active ingredientPharmaceuticalsAntiseizure medicines |
| Schmelzpunkt | 192-194166 - 168 °C166-168°C |
| Physical Description | Solid |
| Dissociation Constants | 13 |
| Collision Cross Section | 165.8 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]169.42 Ų [M-H]- |
| Siedepunkt | 533.8±50.0 °C(Predicted) |
| Dichte | 1.4835 (rough estimate) |
| Brechungsindex | 1.6070 (estimate) |
| Flammpunkt | 11 °C |
| Lagerbedingungen | −20°C |
| pKa (Säurekonstante) | pK1 1.3pK2 11.5(at 25℃) |
| BCS Class | 1 |
| Stabilität | hygroscopic |
| Hauptanwendungen | pharmaceutical |
| InChI | 1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20) |
| InChIKey | DIWRORZWFLOCLC-UHFFFAOYSA-N |
| SMILES | OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O |
| CAS Datenbank | 846-49-1(CAS DataBase Reference) |
| NIST chemische Informationen | Lorazepam(846-49-1) |
| EPA chemische Informationen | Lorazepam (846-49-1) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH361 (93.1%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]P203, P280, P318, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 102 reports by companies from 11 notifications to the ECHA C&L Inventory. |
|---|---|
| Regulatorische Informationen | Hazard Traits - Developmental ToxicityDEA schedule IV controlled substanceLorazepam: Does not have an individual approval but may be used under an appropriate group standard |
| Weitere Sicherheitsinformationen | IMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-: Human health tier I assessment |
| Hazard Classes and Categories | Repr. 2 (93.1%) |
| Treatment | General supportive and symptomatic measures are recommended. Vital signs must be monitored and the patient closely observed. When there is a risk of aspiration, induction of emesis is not recommended. Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. Administration of activated charcoal may also limit drug absorption. (L1712) |
| Gesundheitliche Auswirkungen | They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease. |
| Hepatotoxicity | Lorazepam, as with other benzodiazepines, is rarely associated with serum ALT or alkaline phosphatase elevations during therapy, and considering its widescale use, clinically apparent liver injury from lorazepam is extremely rare. There has been only a single case report of symptomatic, acute liver injury from lorazepam. The latency to onset was 9 months and the clinical pattern that of a self-limited cholestatic hepatitis that resolved within 2 months of stopping. Similar isolated single cases of clinically apparent hepatitis have been reported with other benzodiazepines including alprazolam, chlordiazepoxide, clonazepam, diazepam, flurazepam and triazolam. The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic and mild-to-moderate in severity with a latency of 1 to 6 months. Fever and rash are not common nor is autoantibody formation. |
| Unerwünschte Wirkungen | Similar to most benzodiazepines, lorazepam can induce adverse reactions such as CNS and respiratory depression, which are dose-dependent. Additional adverse effects of the drug are observed with higher doses. |
| Expositionspfade | Parenteral (intravenous, sublingual)oral. Readily absorbed with an absolute bioavailability of 90% when given orally. When intramuscularly administered, lorazepam is completely and rapidly absorbed. It achieves max serum concentration in 3 hours. The max serum concentration of a 4 mg dose is 48 ng/mL. |
| Toxizitätsübersicht | Signs and Symptoms of OverdoseLorazepam binds to an allosteric site on GABA-A receptors, which are pentameric ionotropic receptors in the CNS. Binding potentiates the effects of the inhibitory neurotransmitter GABA, which upon binding opens the chloride channel in the receptor, allowing chloride influx and causing hyperpolerization of the neuron. |
| Signs and Symptoms | Somnolence, confusion, and coma. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)LorazepamvLess-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation◈ What is lorazepam? |
| Toxicity Data | LD50, mouse, oral = 1850 mg/kg LD50: 3178mg/kg (oral, mice) |
| USGS Health-Based Screening Levels for Evaluating Water-Quality | LorazepamPharmaceuticalSmith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP |
| Wassergefährdungsklasse (WGK) | 3 |
| UN-Transportnummer | UN 1230 3/PG 2 |
| Zollcode | 2933910000 |
| RTECS-Nr. | DF0350000 |
| R-Sätze (R) | 63-39/23/24/25-23/24/25-11-36-20/21/22 |
| Toxizität | LD50 in mice, rats (mg/kg): 3178, >5000 orally (Owen) |
| Gefahrensymbole | Xn,T,F |
| Sicherheitshinweise (S) | 36/37-45-16 |
| Lagerklasse | 11 - Combustible Solids |
| Gefahrenklasse | Repr. 2 |
Anwendungen & Verwendung
Verwenden
An anxiolytic, and anticonvulsant. Controlled substance (depressant)